^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CAR.70/IL15-transduced CB-NK cells

    i
    Other names: CAR.70/IL15-transduced CB-NK cells, CAR.70-engineered IL15-transduced cord blood-derived NK cells
    Associations

    News

    Trials
    Company:
    UT MD Anderson Cancer Center
    Drug class:
    NK cell stimulant
    Related drugs:
    Associations

    News

    Trials
    10ms
    Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances (clinicaltrials.gov)
    P1/2, N=94, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Aug 2023 --> Aug 2026 | Trial primary completion date: Aug 2023 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV • CAR.70/IL15-transduced CB-NK cells
    1year
    Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma (clinicaltrials.gov)
    P1/2, N=50, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    cyclophosphamide • fludarabine IV • CAR.70/IL15-transduced CB-NK cells
    over1year
    Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma (clinicaltrials.gov)
    P1/2, N=50, Not yet recruiting, M.D. Anderson Cancer Center
    New P1/2 trial • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    cyclophosphamide • fludarabine IV • CAR.70/IL15-transduced CB-NK cells